This is a high-profile event organized in association with Bloomberg L.P., and attended by an executive-level audience of over 450 investors, pharmas, fund managers and capital-raising companies.

• A series of panels and presentations from leading investment, pharmaceutical and biotechs companies will provide an expert outlook on growth and investment activity in Europe’s Biotech industry, with a specialist panels this year on Investment Trends, Partnerships & Collaborations, Valuation, Global Development. Some provisional speakers presently include:
  - Dr. Holger Reithinger, Investment Director, 3i
  - Dr. Regina Hodits, Principal, Apax Partners
  - Dr. François Thomas, Principal, Atlas Venture
  - Chris Piggott , Senior Director, Global Business Development, Aventis
  - Dr. Chris Henderson, Director Global Licensing, AstraZeneca
  - Prof. Jesper Zeuthen, Managing Director, BankInvest Bio Venture
  - Heinz Michael Meier, Chief Executive, Bayern Kapital GmbH
  - Dr. Jonathan D. Turner, Head of Corporate Dept. Business Development, Boehringer Ingelheim
  - Prof. Dr. Horst Domdey, CEO, Bio-M AG
  - Spiro Rombotis, CEO, Cyclacel
  - Dr Alexander Asam, Partner, DVC Deutsche Venture Capital
  - Dimitri F. Dimitriou, CEO, DyoDelta Biosciences Ltd
  - Dr. Marion Dörner, Principal, Earlybird GmbH & Co. KG
  - Dr. Olaf Bartsch, Vice President Business Development Europe, Genzyme GmbH
  - Dr. Hans A. Küpper, Partner, Global Life Science Ventures GmbH
  - Hanns-Peter Wiese, Partner, Global Life Science Ventures GmbH
  - Chris Britten, Director, GSK Ventures, GlaxoSmithKline
  - Dr. Andreas Wicki, CEO, HBM Partners AG
  - Neil Cohen, General Partner, Israel Seed Partners
  - Stan Yakatan, Chairman, Katan Associates
  - Mark Clement, Chief Executive, Merlin Biosciences
  - Adi Seffer, Partner, Morgan Lewis & Bockius LLP
  - Dr. Christian Zschocke, Managing Partner, Morgan Lewis & Bockius LLP
  - Dr. Ansbert Gadicke, Founding General Partner, MPM Capital
  - Dr. Samir Master, M.D., Vice President, Business Development & Licensing, Head Biotechnology & Speciality Pharmaceuticals, Novartis Pharma, AG
  - Dr. Christoph H. Westphal, General Partner, Polaris Venture Partners
  - Simon Sturge, CEO, Vernalis
  - N. Peter Kostopulos, Partner, Womble Carlyle Sandridge & Rice, PLLC
  and Chairman, Strategic Alliance Committee of the Licensing Executives Society
  - Frances Bornstein, Vice President, Head of Issuers and Investor Relations, SWX Swiss Exchange
  - Dr. Helmut M Schühsler, Managing Partner, Techno Venture Management
  - Michel Hubert, Vice President, Business Development, Transgene
  - Nick Lowcock, Managing Director, Warburg Pincus International LLC
  - Dr. Ben Bronstein, Managing Director, Zero Stage Capital

• Sector specific workshops will feature over 50 biotech company presentations, offering investors & pharmas an excellent opportunity to review an exciting range of emerging life science companies looking to raise capital and/or partner. Sectors include:
  - Immunology/Oncology
  - Therapeutics
  - Post-Genomics: Pharmacogenomics/Proteomics
  - Medical Devices/Diagnostics
  - Bioinformatics/SNP/Array Technology

• A special ‘Institutional Investor Summit’ will focus primarily on M&A and market consolidation, with a series of in- depth discussions from leading institutional investors, fund managers and fund of funds.

• The Summit will also feature a focus session for ‘Small-Cap/IPO’ biotech companies.